Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics


Theravance Biopharma, Inc. - Ordinary Shares (TBPH): $7.11

0.25 (+3.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TBPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

TBPH POWR Grades


  • Growth is the dimension where TBPH ranks best; there it ranks ahead of 70.29% of US stocks.
  • The strongest trend for TBPH is in Momentum, which has been heading down over the past 47 weeks.
  • TBPH's current lowest rank is in the Momentum metric (where it is better than 9.67% of US stocks).

TBPH Stock Summary

  • Theravance Biopharma Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.9% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.44 for Theravance Biopharma Inc; that's greater than it is for just 4.38% of US stocks.
  • As for revenue growth, note that TBPH's revenue has grown -16.46% over the past 12 months; that beats the revenue growth of merely 13.77% of US companies in our set.
  • Stocks that are quantitatively similar to TBPH, based on their financial statements, market capitalization, and price volatility, are EVGN, BBIO, OTIC, APTX, and AGIO.
  • Visit TBPH's SEC page to see the company's official filings. To visit the company's web site, go to www.theravance.com.

TBPH Valuation Summary

  • TBPH's price/sales ratio is 9.5; this is 150% higher than that of the median Healthcare stock.
  • Over the past 89 months, TBPH's price/sales ratio has gone down 3267.9.
  • TBPH's EV/EBIT ratio has moved down 0 over the prior 89 months.

Below are key valuation metrics over time for TBPH.

Stock Date P/S P/B P/E EV/EBIT
TBPH 2021-08-31 9.5 -2.0 -2.3 -4.7
TBPH 2021-08-30 9.6 -2.1 -2.3 -4.8
TBPH 2021-08-27 9.4 -2.0 -2.3 -4.7
TBPH 2021-08-26 9.4 -2.0 -2.3 -4.7
TBPH 2021-08-25 10.0 -2.1 -2.4 -4.9
TBPH 2021-08-24 10.6 -2.3 -2.6 -5.0

TBPH Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at -109.59%.
  • Its 3 year revenue growth rate is now at 42.99%.
  • Its 2 year net income to common stockholders growth rate is now at 13.41%.
Over the past 33 months, TBPH's revenue has gone up $15,010,000.

The table below shows TBPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 64.158 -261.934 -264.161
2021-03-31 66.252 -265.167 -274.643
2020-12-31 71.857 -250.403 -278.017
2020-09-30 82.626 -249.83 -285.189
2020-06-30 76.796 -217.421 -269.977
2020-03-31 87.938 -212.105 -246.928

TBPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TBPH has a Quality Grade of C, ranking ahead of 25% of graded US stocks.
  • TBPH's asset turnover comes in at 0.144 -- ranking 229th of 677 Pharmaceutical Products stocks.
  • AVTX, SUPN, and NBIX are the stocks whose asset turnover ratios are most correlated with TBPH.

The table below shows TBPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.144 1 -0.253
2021-03-31 0.138 1 -0.250
2020-12-31 0.134 1 -0.257
2020-09-30 0.158 1 -0.273
2020-06-30 0.152 1 -0.285
2020-03-31 0.180 1 -0.288

TBPH Price Target

For more insight on analysts targets of TBPH, see our TBPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.56 Average Broker Recommendation 1.78 (Moderate Buy)

TBPH Stock Price Chart Interactive Chart >

Price chart for TBPH

TBPH Price/Volume Stats

Current price $7.11 52-week high $22.74
Prev. close $6.86 52-week low $6.10
Day low $6.77 Volume 2,797,600
Day high $7.27 Avg. volume 660,600
50-day MA $11.60 Dividend yield N/A
200-day MA $16.90 Market Cap 522.37M

Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio


Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.


TBPH Latest News Stream


Event/Time News Detail
Loading, please wait...

TBPH Latest Social Stream


Loading social stream, please wait...

View Full TBPH Social Stream

Latest TBPH News From Around the Web

Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

Yahoo | September 16, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | September 15, 2021

Why Theravance Biopharma Stock Dived 16% Today

Shares of Theravance Bipharma (NASDAQ: TBPH) really took it on the chin Wednesday. This morning, Theravance divulged the top-line results from its phase 3 study of Ampreloxetine, a drug aimed at treating symptomatic neurogenic orthostatic hypotension (nOH, essentially a disorder in which the body does not effectively regulate blood pressure). Theravance admitted that the drug did not meet its primary endpoint of improving nOH in patients suffering from the disorder.

Yahoo | September 15, 2021

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

Yahoo | September 15, 2021

Theravance Biopharma shares slide 34% premarket on news to cut 75% of workforce in strategic overhaul

Theravance Biopharma Inc. shares slid 34% in premarket trade Wednesday, after the company announced a major overhaul of its business including reducing its headcount by about 75%, or 270 jobs. The company is also cutting two long-term directors from its board and will focus its R&D effort on its core respiratory assets. The changes come after a review of the business led by the board and management with the help of outside advisers. The stock fell more than 30% in a day in August after it announ

Yahoo | September 15, 2021

Read More 'TBPH' Stories Here

TBPH Price Returns

1-mo -47.29%
3-mo -59.42%
6-mo -65.18%
1-year -60.10%
3-year -74.15%
5-year -78.88%
YTD -59.99%
2020 -31.36%
2019 1.17%
2018 -8.25%
2017 -12.52%
2016 94.51%

Continue Researching TBPH

Here are a few links from around the web to help you further your research on Theravance Biopharma Inc's stock as an investment opportunity:

Theravance Biopharma Inc (TBPH) Stock Price | Nasdaq
Theravance Biopharma Inc (TBPH) Stock Quote, History and News - Yahoo Finance
Theravance Biopharma Inc (TBPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3525 seconds.